Endometrial Carcinoma: Epidemiology and Risk Factors

  • Ritu Khatuja
  • Swati Rai


Endometrial cancer is one of the important cancers in women of developed countries, but its incidence in developing or underdeveloped countries is low. With the change in lifestyle and dietary habits, there is a change in trend of the disease in various countries. Most cases of endometrial cancers present at early stages and are generally associated with good prognosis; hence, mortality and morbidity are low. The commonest type of endometrial malignancy is endometrioid type (type I) which is predominantly estrogen dependent, and any condition leading to increase in estrogen whether endogenous or exogenous can lead to endometrial malignancy. In this chapter, we will be detailing the epidemiology of the disease as well as various risk factors that are causative for development of endometrial carcinoma.


Endometrial carcinoma Epidemiology Risk factors Estrogen Progesterone 


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. Scholar
  3. 3.
    Terri M, David S, Sherman AJ, Ann GS, Stephen BG. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am. J Public Health. 2014;94:2104–11.Google Scholar
  4. 4.
    Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. Scholar
  5. 5.
    Sheikh MA, Althouse AD, Freese KE, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol. 2014;10(16):2561–8. Scholar
  6. 6.
    Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003;53:27–43.CrossRefGoogle Scholar
  7. 7.
    Zeleniuch-Jacquotte A, Lundin E, et al. Circulating enterolactone and risk of endometrial cancer. Int J Cancer. 2006;119:2376–81.CrossRefGoogle Scholar
  8. 8.
  9. 9.
    Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338–66. Scholar
  10. 10.
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10.CrossRefGoogle Scholar
  11. 11.
    Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21:1851.CrossRefGoogle Scholar
  12. 12.
    Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr. 1987;45:277.CrossRefGoogle Scholar
  13. 13.
    Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer. 2001;84:975.CrossRefGoogle Scholar
  14. 14.
    Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.CrossRefGoogle Scholar
  15. 15.
    Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569.CrossRefGoogle Scholar
  16. 16.
    Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol. 2005;193:1640.CrossRefGoogle Scholar
  17. 17.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med. 2003;348:1625–38.CrossRefGoogle Scholar
  18. 18.
    Pillay OC, Te Fong LF, Crow JC, et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod. 2006;21:924–9.CrossRefGoogle Scholar
  19. 19.
    Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361:1810–2.CrossRefGoogle Scholar
  20. 20.
    Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167:1317.CrossRefGoogle Scholar
  21. 21.
    Xu WH, Xiang YB, Ruan ZX, et al. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. Int J Cancer. 2004;108:613.CrossRefGoogle Scholar
  22. 22.
    Karageorgi S, Hankinson SE, Kraft P, de Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976–2004. Int J Cancer. 2010;126:208.CrossRefGoogle Scholar
  23. 23.
    Pettersson B, Adami HO, Bergstrom R, Johansson ED. Menstruation span ± a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynaecol Scand. 1986;65:247–55.CrossRefGoogle Scholar
  24. 24.
    Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180.CrossRefGoogle Scholar
  25. 25.
    Lucenteforte E, Talamini R, Montella M, et al. Family history of cancer and the risk of endometrial cancer. Eur J Cancer Prev. 2009;18:95.CrossRefGoogle Scholar
  26. 26.
    Mucci LA, Hjelmborg JB, Harris JR, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315:68.CrossRefGoogle Scholar
  27. 27.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.CrossRefGoogle Scholar
  28. 28.
    Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105–10. J Med Genet 2013; 50, 255–263CrossRefGoogle Scholar
  29. 29.
    Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127:17–25.CrossRefGoogle Scholar
  30. 30.
    Thompson D, Easton DF. Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358.CrossRefGoogle Scholar
  31. 31.
    Beiner ME, Finch A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104:7.CrossRefGoogle Scholar
  32. 32.
    Hanssen AM, Fryns JP. Cowden syndrome. J Med Genet. 1995;32:117–9.CrossRefGoogle Scholar
  33. 33.
    Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50:255–63.CrossRefGoogle Scholar
  34. 34.
    Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139:1927.CrossRefGoogle Scholar
  35. 35.
    Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010;8:6.39: 1927CrossRefGoogle Scholar
  36. 36.
    Lim W, Hearle N, Shah B, et al. Further observations on LKB1/STK11 status and cancer risk in Peutz–Jeghers syndrome. Br J Cancer. 2003;89:308–13.CrossRefGoogle Scholar
  37. 37.
    Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447–53.CrossRefGoogle Scholar
  38. 38.
    Bandera EV, Kushi LH, Moore DF, et al. Consumption of animal foods and endometrial cancer risk: a systematic literature review and meta-analysis. Cancer Causes Control. 2007;18:967.CrossRefGoogle Scholar
  39. 39.
    Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. Br J Cancer. 2008;99:434.CrossRefGoogle Scholar
  40. 40.
    Loerbroks A, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking, and endometrial cancer risk: results from the Netherlands Cohort Study. Cancer Causes Control. 2007;18:551.CrossRefGoogle Scholar
  41. 41.
    Sun Q, Xu L, Zhou B, et al. Alcohol consumption and the risk of endometrial cancer: a meta-analysis. Asia Pac J Clin Nutr. 2011;20:125.PubMedGoogle Scholar
  42. 42.
    Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2009;2:CD000402.Google Scholar
  43. 43.
    Voigt LF, Weiss NS, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991;338:274.CrossRefGoogle Scholar
  44. 44.
    Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989;298:147.CrossRefGoogle Scholar
  45. 45.
    Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543.CrossRefGoogle Scholar
  46. 46.
    Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2003;290:1739.CrossRefGoogle Scholar
  47. 47.
    Iqbal J, Ginsburg OM, Wijeratne TD, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012;38:318.CrossRefGoogle Scholar
  48. 48.
    Barakat RR, Wong G, Curtin JP, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994;55:164.CrossRefGoogle Scholar
  49. 49.
    Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol. 2014; 123:1394.Google Scholar
  50. 50.
    Horn-Ross PL, John EM, Canchola AJ, et al. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003;95:1158.CrossRefGoogle Scholar
  51. 51.
    Myung SK, Ju W, Choi HJ, et al. Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis. BJOG. 2009;116:1697.CrossRefGoogle Scholar
  52. 52.
    North American Menopause Society. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause. 2011;18:732.CrossRefGoogle Scholar
  53. 53.
    Parazzini F, Negri E, La Vecchia C, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer. 1998;76:784.CrossRefGoogle Scholar
  54. 54.
    Henderson BE, Casagrande JT, Pike MC, et al. The epidemiology of endometrial cancer in young women. Br J Cancer. 1983;47:749–56.CrossRefGoogle Scholar
  55. 55.
    Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50:1365.CrossRefGoogle Scholar
  56. 56.
    Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008;98:1582.CrossRefGoogle Scholar
  57. 57.
    Liang SX, Pearl M, Liang S, et al. Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Int J Cancer. 2011;128:763.CrossRefGoogle Scholar
  58. 58.
    Winer I, Lehman A, Wactawski-Wende J, et al. Tubal ligation and risk of endometrial cancer: findings from the Women’s Health Initiative. Int J Gynecol Cancer. 2016;26:464.CrossRefGoogle Scholar
  59. 59.
    Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. Gynecol Oncol. 2013;128:71.CrossRefGoogle Scholar
  60. 60.
    Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. Br J Hosp Med. 1997;59:1055–60.Google Scholar
  61. 61.
    Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061.CrossRefGoogle Scholar
  62. 62.
    Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216:580.e1.CrossRefGoogle Scholar
  63. 63.
    Soini T, Hurskainen R, Grénman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124:292.CrossRefGoogle Scholar
  64. 64.
    Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651.CrossRefGoogle Scholar
  65. 65.
    Setiawan VW, Pike MC, Karageorgi S, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol. 2012;176:269.CrossRefGoogle Scholar
  66. 66.
    Jordan SJ, Na R, Johnatty SE, et al. Breastfeeding and endometrial cancer risk: an analysis from the epidemiology of endometrial cancer consortium. Obstet Gynecol. 2017;129:1059.CrossRefGoogle Scholar
  67. 67.
    Zhou B, Yang L, Sun Q, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121:501.CrossRefGoogle Scholar
  68. 68.
    Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132:3456S.CrossRefGoogle Scholar
  69. 69.
    Bravi F, Scotti L, Bosetti C, et al. Coffee drinking and endometrial cancer risk: a meta-analysis of observational studies. Am J Obstet Gynecol. 2009;200:130.CrossRefGoogle Scholar
  70. 70.
    Butler LM, Wu AH. Green and black tea in relation to gynecologic cancers. Mol Nutr Food Res. 2011;55:931.CrossRefGoogle Scholar
  71. 71.
    McCullough ML, Bandera EV, Moore DF, Kushi LH. Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature. Prev Med. 2008;46:298.CrossRefGoogle Scholar
  72. 72.
    Matsuo K, Cahoon SS, Yoshihara K, et al. Association of low-dose aspirin and survival of women with endometrial cancer. Obstet Gynecol. 2016;128:127.CrossRefGoogle Scholar
  73. 73.
    Podratz KC, Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol Oncol. 2003;91:461.CrossRefGoogle Scholar
  74. 74.
    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomark Prev. 2002;11:1531–43.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Ritu Khatuja
    • 1
  • Swati Rai
    • 2
  1. 1.Department of Obstetrics and GynaecologyANIIMSPort BlairIndia
  2. 2.Department of Obstetrics and GynaecologyMaulana Azad Medical College and Lok Nayak HospitalNew DelhiIndia

Personalised recommendations